Similar to CXCL12 signaling inhibition, blocking TGF-β signaling resulted in more T-cell infiltration and increased sensitivity to checkpoint inhibition therapy in multiple mouse models for breast cancer and colorectal cancer [150,151,152]. This evidence concerns the gene CXCL12 and colorectal cancer.